

Product Name: SB 706504

Catalog No.: 5040


Batch No.: 1

CAS Number: 911110-38-8

IUPAC Name: *N*-Cyano-*N'*-[2-[[8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7,8-dihydro-7-oxopyrido[2,3-*d*]pyrimidin-2-yl]amino]ethyl]guanidine

1. PHYSICAL AND CHEMICAL PROPERTIES

Batch Molecular Formula:	C ₂₄ H ₁₉ F ₃ N ₈ O.0.33CH ₃ CH ₂ OH.¼H ₂ O
Batch Molecular Weight:	512.32
Physical Appearance:	White solid
Solubility:	DMSO to 100 mM
Storage:	Desiccate at RT
Batch Molecular Structure:	



2. ANALYTICAL DATA

TLC:	R _f = 0.27 (Dichloromethane:Methanol [95:5])
HPLC:	Shows 98.1% purity
¹H NMR:	Consistent with structure
Mass Spectrum:	Consistent with structure
Microanalysis:	

	Carbon	Hydrogen	Nitrogen
Theoretical	57.83	4.23	21.88
Found	57.65	4.15	21.77

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use

Product Name: SB 706504

Catalog No.: 5040

Batch No.: 1

CAS Number: 911110-38-8

IUPAC Name: *N*-Cyano-*N'*-[2-[[8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7,8-dihydro-7-oxopyrido[2,3-*d*]pyrimidin-2-yl]amino]ethyl]guanidine

Description:

p38 MAPK inhibitor. Inhibits LPS-induced transcription of a range of chemokines and cytokines in chronic obstructive pulmonary disease (COPD) monocyte derived macrophages (MDMs). Also inhibits LPS-induced protein expression of IL-6, IL-10, TNF α and γ -inducible protein 10 in COPD MDMs. Effects on suppression of LPS-induced gene and protein expression are enhanced in combination with dexamethasone (Cat. No. 1126).

Physical and Chemical Properties:


Batch Molecular Formula: C₂₄H₁₉F₃N₃O.0.33CH₃CH₂OH.¼H₂O

Batch Molecular Weight: 512.32

Physical Appearance: White solid

Minimum Purity: ≥98%

Batch Molecular Structure:



Storage: Desiccate at RT

Solubility & Usage Info:

DMSO to 100 mM

Stability and Solubility Advice:

Some solutions can be difficult to obtain and can be encouraged by rapid stirring, sonication or gentle warming (in a 45-60°C water bath).

Information concerning product stability, particularly in solution, has rarely been reported and in most cases we can only offer a general guide. Our standard recommendations are:

SOLIDS: Provided storage is as stated on the product label and the vial is kept tightly sealed, the product can be stored for up to 6 months from date of receipt.

SOLUTIONS: We recommend that stock solutions, once prepared, are stored aliquoted in tightly sealed vials at -20°C or below and used within 1 month. Wherever possible solutions should be made up and used on the same day.

Licensing Information:

Sold for research purposes under agreement from GlaxoSmithKline

References:

Kent et al (2009) Inhibition of lipopolysaccharide-stimulated chronic obstructive pulmonary disease macrophage inflammatory gene expression by dexameth. and the p38 mitogen-activated protein kinase inhibitor *N*-cyano-*N'*-(2-[[8-(2,6-difluorophenyl)] J.Pharmacol.Exp.Ther. **328** 458. PMID: 19004925.

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use

bio-techne.com

info@bio-techne.com

techsupport@bio-techne.com

North America

Tel: (800) 343 7475

China

info.cn@bio-techne.com

Tel: +86 (21) 52380373

Europe Middle East Africa

Tel: +44 (0)1235 529449

Rest of World

www.tocris.com/distributors

Tel:+1 612 379 2956